Correlation of the MMP-2 variant -1306T with the presence of diabetic polyneuropathy_
| Genotype | Patients n (%) | Controls n ( %) | p-value or (95 % CI) |
|---|---|---|---|
| -1306CC | 22 (75.86) | 27 (48.21) | 0.0170٭ |
| -1306TC and -1306TT | 7 (24.14) | 29 (51.79) | 0.2962 (0.1091-0.8045) |
Genotype distrubution of the MMP-2 and MMP-9 gene variants in patients with diabetes and in the control group_
| Genotype | Patients n (%) | Controls n (%) | P-value OR (95 % CI) patients vs. control * |
|---|---|---|---|
| MMP-2 | |||
| -1306CC | 53 (67.1) | 27 (48) | 0.028 |
| -1306CT | 24 (30.4) | 25 (45) | 0.457 (0.226-0.932) |
| -1306TT | 2 ( 2.5) | 4 (7) | |
| MMP-9 | |||
| -1562CC | 56 (71) | 40 (71) | 0.945 |
| -1562CT | 20 (25) | 16 (29) | 1.27 (0.482-2.187) |
| -1562TT | 3 (4) | 0 (0) | |
Demographic and clinical characteristics of patients_
| Variable | Values |
|---|---|
| Age, mean± SD | 61.4 ± 7.3 |
| Gender, male n (%) female n ( %) | 65 (63.7) 37 (36.3) |
| Smokers, n (%) | 23 (22.5) |
| Diabetes duration, mean± SD | 10.1±5.8 |
| BMI, mean± SD | 28.8±4.8 |
| HbA1c, mean± SD | 9.40±2.22 |
| FBG, mean± SD | 6.90±1.94 |
| Total cholesterol (mmol/l), mean± SD | 5.20±1.35 |
| LDLc (mmol/l), mean± SD | 3.11±1.03 |
| HDLc (mmol/l), mean± SD | 1.15±0.30 |
| Triglycerides (mmol/l), mean± SD | 2.25±1.16 |
| Albumin mg/24h/urine, mean± SD | 12.54±2.79 |
| Serum creatinine (μmol/l), mean± SD | 87.81±42.75 |
| OAD only, n (%) | 23 (22.5) |
| Insulin only, n (%) | 14 (13.7) |
| OAD + insulin, n (%) | 65 (63.7) |
| Metformin, n (%) | 88 (86.3) |
| Retinopathy non-proliferative, n (%) | 21 (20.6) |
| Retinopathy proliferative, n (%) | 9 (8.8) |
| Polyneuropathy, n (%) | 40 (39.2) |
| Nephropathy, n (%) | 11 (10.8) |